|

JS207 Clinical Trials

6 actively recruiting trials

▼ -1 trial since August 2026

Pipeline

Phase 2: 5Phase 1/2: 1

Top Sponsors

  • Shanghai Junshi Bioscience Co., Ltd.4
  • Mabwell (Shanghai) Bioscience Co., Ltd.1
  • Fudan University1

Indications

  • Cancer6
  • Liver Disease1
  • Hormone Receptor Negative Tumor1
  • Non-Squamous Non-Small Cell Lung Cancer1
  • Hormone Receptor Positive Tumor1

Other6 trials

A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer
Phase 2
A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors
Phase 1/2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2
JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
Phase 2
JS212 Combination Therapies in Metastatic Colorectal Cancer
Phase 2
Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.